Researchers at NYU Langone Health found that 63% of patients receiving a commonly prescribed focal epilepsy treatment, levetiracetam, continued to experience seizure symptoms for a year on average until they received the correct dosage of drugs — or in some cases, until they tried a different kind of treatment altogether. Neurologists often start patients on levetiracetam, an oral formulation to treat focal epilepsy. But in the study, only a quarter of the 57% of participants on levetiracetam became seizure-free immediately after starting the medication. “There have been several studies on focal epilepsy,” Jacqueline French, an epileptologist at NYU Langone Comprehensive Epilepsy Center, wrote in a statement to WSN. As the work was ongoing, the research team continued looking into new ways to relieve seizure patients of seizures and examined different types of medicine and dosages.